Sartorius Stedim Biotech acquires Cellca
Sartorius Stedim Biotech (SSB), a leading international supplier for the pharma and biotech industries, acquired Cellca GmbH based in Laupheim, Germany, last Wednesday. Founded in 2005, the company with around 30 employees generated sales revenue of approximately 6 million euros in 2014.
Cellca’s major customers are biopharmaceutical companies as well as biosimilar firms that do not or only partly conduct their process development in their in-house facilities. Through this acquisition, Sartorius Stedim Biotech is further expanding its service offering for process development. SSB has already strengthened this segment by its two recent acquisitions of BioOutsource and TAP Biosystems.
Reinhard Vogt, member of the SSB Executive Committee for Marketing and Sales, commented, “Together with our single-use products, media and testing services, we are creating an attractive package, above all for young biopharmaceutical companies that need robust processes for the manufacture of their biologics."
“Due to its global presence and high reputation, Sartorius Stedim Biotech is an ideal partner for Cellca. We now have a strong base to further expand and develop our business internationally,” said Hugo de Wit, the Managing Director of Cellca.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
